APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Diagnostics

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

Selected research

Market Analysis & Forecast

Global Prostate Cancer Diagnostics Market Analysis and Forecast 2026-2032

Report ID 173895340225 December 2025197 pages

Choose your research edition.

Industry ResearchProstate Cancer Diagnostics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Diagnostics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Diagnostics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Diagnostics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.

Read the full market overview

Report Includes

This report presents an overview of global market for Prostate Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Prostate Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Prostate Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

Prostate Cancer Diagnostics Segment by Company

OPKO

Genomic Health

Abbott

Beckman Coulter

Siemens Healthcare

bioMeriux

Roche

MDx Health

DiaSorin

Myriad Genetics

Ambry Genetics

Prostate Cancer Diagnostics Segment by Type

Tumor Biomarker Tests

Imaging

Biopsy

Other

Prostate Cancer Diagnostics Segment by Application

Age Below 55

Age 55-75

Age Above 75

Prostate Cancer Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Prostate Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tumor Biomarker Tests Major Player Table 3. Imaging Major Player Table 4. Biopsy Major Player Table 5. Other Major Player Table 6. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Age Below 55 Major Player Table 8. Age 55-75 Major Player Table 9. Age Above 75 Major Player Table 10. Prostate Cancer Diagnostics Industry Trends Table 11. Prostate Cancer Diagnostics Industry Drivers Table 12. Prostate Cancer Diagnostics Industry Opportunities and Challenges Table 13. Prostate Cancer Diagnostics Industry Restraints Table 14. Global Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Prostate Cancer Diagnostics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Prostate Cancer Diagnostics Market Share by Region (2021-2026) Table 17. Global Prostate Cancer Diagnostics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Prostate Cancer Diagnostics Market Share by Region (2027-2032) Table 19. Global Prostate Cancer Diagnostics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Prostate Cancer Diagnostics Revenue Market Share by Players (2021-2026) Table 21. Global Prostate Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served Table 23. Global Prostate Cancer Diagnostics Players, Product Type & Application Table 24. Global Prostate Cancer Diagnostics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Prostate Cancer Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Prostate Cancer Diagnostics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2021-2026) Table 31. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2027-2032) Table 32. Global Prostate Cancer Diagnostics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2021-2026) Table 36. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2027-2032) Table 37. OPKO Company Information Table 38. OPKO Business Overview Table 39. OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. OPKO Prostate Cancer Diagnostics Product Portfolio Table 41. OPKO Recent Development Table 42. Genomic Health Company Information Table 43. Genomic Health Business Overview Table 44. Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Genomic Health Prostate Cancer Diagnostics Product Portfolio Table 46. Genomic Health Recent Development Table 47. Abbott Company Information Table 48. Abbott Business Overview Table 49. Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Abbott Prostate Cancer Diagnostics Product Portfolio Table 51. Abbott Recent Development Table 52. Beckman Coulter Company Information Table 53. Beckman Coulter Business Overview Table 54. Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio Table 56. Beckman Coulter Recent Development Table 57. Siemens Healthcare Company Information Table 58. Siemens Healthcare Business Overview Table 59. Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio Table 61. Siemens Healthcare Recent Development Table 62. bioMeriux Company Information Table 63. bioMeriux Business Overview Table 64. bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. bioMeriux Prostate Cancer Diagnostics Product Portfolio Table 66. bioMeriux Recent Development Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Roche Prostate Cancer Diagnostics Product Portfolio Table 71. Roche Recent Development Table 72. MDx Health Company Information Table 73. MDx Health Business Overview Table 74. MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. MDx Health Prostate Cancer Diagnostics Product Portfolio Table 76. MDx Health Recent Development Table 77. DiaSorin Company Information Table 78. DiaSorin Business Overview Table 79. DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. DiaSorin Prostate Cancer Diagnostics Product Portfolio Table 81. DiaSorin Recent Development Table 82. Myriad Genetics Company Information Table 83. Myriad Genetics Business Overview Table 84. Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio Table 86. Myriad Genetics Recent Development Table 87. Ambry Genetics Company Information Table 88. Ambry Genetics Business Overview Table 89. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio Table 91. Ambry Genetics Recent Development Table 92. North America Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Prostate Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Prostate Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Prostate Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Prostate Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 106. China Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 107. China Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 108. China Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 109. China Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Prostate Cancer Diagnostics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Prostate Cancer Diagnostics Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Prostate Cancer Diagnostics Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Prostate Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Prostate Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Prostate Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Prostate Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Prostate Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Prostate Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Prostate Cancer Diagnostics Image Figure 2. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tumor Biomarker Tests Image Figure 5. Imaging Image Figure 6. Biopsy Image Figure 7. Other Image Figure 8. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Prostate Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Age Below 55 Image Figure 11. Age 55-75 Image Figure 12. Age Above 75 Image Figure 13. Global Prostate Cancer Diagnostics Market Size (US$ Million) & (2021-2032) Figure 14. Global Prostate Cancer Diagnostics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Prostate Cancer Diagnostics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Prostate Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2021-2032) Figure 21. Global Prostate Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2021-2032) Figure 24. North America Prostate Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Prostate Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 26. North America Prostate Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 27. North America Prostate Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 28. United States Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Prostate Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Prostate Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 33. Europe Prostate Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 34. Europe Prostate Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 35. Germany Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Prostate Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Prostate Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 45. China Prostate Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 46. Asia Prostate Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Prostate Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 48. Asia Prostate Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 49. Asia Prostate Cancer Diagnostics Revenue Share by Region (2021-2032) Figure 50. Japan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Prostate Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Prostate Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 58. SAMEA Prostate Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 59. SAMEA Prostate Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 60. Brazil Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tumor Biomarker Tests
  • Imaging
  • Biopsy
  • Other
Applications
  • Age Below 55
  • Age 55-75
  • Age Above 75
Companies covered
  • OPKO
  • Genomic Health
  • Abbott
  • Beckman Coulter
  • Siemens Healthcare
  • bioMeriux
  • Roche
  • MDx Health
  • DiaSorin
  • Myriad Genetics
  • Ambry Genetics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Prostate Cancer Diagnostics Market by Type
  3. 1.2.1 Global Prostate Cancer Diagnostics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tumor Biomarker Tests
  5. 1.2.3 Imaging
  6. 1.2.4 Biopsy
  7. 1.2.5 Other
  8. 1.3 Prostate Cancer Diagnostics Market by Application
  9. 1.3.1 Global Prostate Cancer Diagnostics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Age Below 55
  11. 1.3.3 Age 55-75
  12. 1.3.4 Age Above 75
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Prostate Cancer Diagnostics Market Dynamics
  1. 2.1 Prostate Cancer Diagnostics Industry Trends
  2. 2.2 Prostate Cancer Diagnostics Industry Drivers
  3. 2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 Prostate Cancer Diagnostics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Prostate Cancer Diagnostics Market Perspective (2021-2032)
  2. 3.2 Global Prostate Cancer Diagnostics Growth Trends by Region
  3. 3.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Prostate Cancer Diagnostics Market Size by Region (2021-2026)
  5. 3.2.3 Global Prostate Cancer Diagnostics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Prostate Cancer Diagnostics Revenue by Players
  2. 4.1.1 Global Prostate Cancer Diagnostics Revenue by Players (2021-2026)
  3. 4.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Prostate Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
  7. 4.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
  8. 4.5 Global Prostate Cancer Diagnostics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
  11. 4.6.3 2025 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier 3
5 Prostate Cancer Diagnostics Market Size by Type
  1. 5.1 Global Prostate Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 5.3 Global Prostate Cancer Diagnostics Revenue Market Share by Type (2021-2032)
6 Prostate Cancer Diagnostics Market Size by Application
  1. 6.1 Global Prostate Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  3. 6.3 Global Prostate Cancer Diagnostics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 OPKO
  2. 7.1.1 OPKO Company Information
  3. 7.1.2 OPKO Business Overview
  4. 7.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
  6. 7.1.5 OPKO Recent Developments
  7. 7.2 Genomic Health
  8. 7.2.1 Genomic Health Company Information
  9. 7.2.2 Genomic Health Business Overview
  10. 7.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
  12. 7.2.5 Genomic Health Recent Developments
  13. 7.3 Abbott
  14. 7.3.1 Abbott Company Information
  15. 7.3.2 Abbott Business Overview
  16. 7.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
  18. 7.3.5 Abbott Recent Developments
  19. 7.4 Beckman Coulter
  20. 7.4.1 Beckman Coulter Company Information
  21. 7.4.2 Beckman Coulter Business Overview
  22. 7.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
  24. 7.4.5 Beckman Coulter Recent Developments
  25. 7.5 Siemens Healthcare
  26. 7.5.1 Siemens Healthcare Company Information
  27. 7.5.2 Siemens Healthcare Business Overview
  28. 7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
  30. 7.5.5 Siemens Healthcare Recent Developments
  31. 7.6 bioMeriux
  32. 7.6.1 bioMeriux Company Information
  33. 7.6.2 bioMeriux Business Overview
  34. 7.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
  36. 7.6.5 bioMeriux Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 MDx Health
  44. 7.8.1 MDx Health Company Information
  45. 7.8.2 MDx Health Business Overview
  46. 7.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
  48. 7.8.5 MDx Health Recent Developments
  49. 7.9 DiaSorin
  50. 7.9.1 DiaSorin Company Information
  51. 7.9.2 DiaSorin Business Overview
  52. 7.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
  54. 7.9.5 DiaSorin Recent Developments
  55. 7.10 Myriad Genetics
  56. 7.10.1 Myriad Genetics Company Information
  57. 7.10.2 Myriad Genetics Business Overview
  58. 7.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
  60. 7.10.5 Myriad Genetics Recent Developments
  61. 7.11 Ambry Genetics
  62. 7.11.1 Ambry Genetics Company Information
  63. 7.11.2 Ambry Genetics Business Overview
  64. 7.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
  66. 7.11.5 Ambry Genetics Recent Developments
8 North America
  1. 8.1 North America Prostate Cancer Diagnostics Revenue (2021-2032)
  2. 8.2 North America Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 8.2.1 North America Prostate Cancer Diagnostics Revenue by Type (2021-2026)
  4. 8.2.2 North America Prostate Cancer Diagnostics Revenue by Type (2027-2032)
  5. 8.3 North America Prostate Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 8.4 North America Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  7. 8.4.1 North America Prostate Cancer Diagnostics Revenue by Application (2021-2026)
  8. 8.4.2 North America Prostate Cancer Diagnostics Revenue by Application (2027-2032)
  9. 8.5 North America Prostate Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 8.6 North America Prostate Cancer Diagnostics Revenue by Country
  11. 8.6.1 North America Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Prostate Cancer Diagnostics Revenue by Country (2021-2026)
  13. 8.6.3 North America Prostate Cancer Diagnostics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Prostate Cancer Diagnostics Revenue (2021-2032)
  2. 9.2 Europe Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Prostate Cancer Diagnostics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Prostate Cancer Diagnostics Revenue by Type (2027-2032)
  5. 9.3 Europe Prostate Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Prostate Cancer Diagnostics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Prostate Cancer Diagnostics Revenue by Application (2027-2032)
  9. 9.5 Europe Prostate Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Prostate Cancer Diagnostics Revenue by Country
  11. 9.6.1 Europe Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Prostate Cancer Diagnostics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Prostate Cancer Diagnostics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Prostate Cancer Diagnostics Revenue (2021-2032)
  2. 10.2 China Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 10.2.1 China Prostate Cancer Diagnostics Revenue by Type (2021-2026)
  4. 10.2.2 China Prostate Cancer Diagnostics Revenue by Type (2027-2032)
  5. 10.3 China Prostate Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 10.4 China Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  7. 10.4.1 China Prostate Cancer Diagnostics Revenue by Application (2021-2026)
  8. 10.4.2 China Prostate Cancer Diagnostics Revenue by Application (2027-2032)
  9. 10.5 China Prostate Cancer Diagnostics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Prostate Cancer Diagnostics Revenue (2021-2032)
  2. 11.2 Asia Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Prostate Cancer Diagnostics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Prostate Cancer Diagnostics Revenue by Type (2027-2032)
  5. 11.3 Asia Prostate Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Prostate Cancer Diagnostics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Prostate Cancer Diagnostics Revenue by Application (2027-2032)
  9. 11.5 Asia Prostate Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Prostate Cancer Diagnostics Revenue by Country
  11. 11.6.1 Asia Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Prostate Cancer Diagnostics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Prostate Cancer Diagnostics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Prostate Cancer Diagnostics Revenue (2021-2032)
  2. 12.2 SAMEA Prostate Cancer Diagnostics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Prostate Cancer Diagnostics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Prostate Cancer Diagnostics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Prostate Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Prostate Cancer Diagnostics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Prostate Cancer Diagnostics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Prostate Cancer Diagnostics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Prostate Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Prostate Cancer Diagnostics Revenue by Country
  11. 12.6.1 SAMEA Prostate Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Prostate Cancer Diagnostics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Prostate Cancer Diagnostics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst